2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17521
    Flumorph 211867-47-9 99.57%
    Flumorph(SYP-L190) is a carboxylic acid amide (CAA) fungicide.
    Flumorph
  • HY-17525
    Bethoxazin 163269-30-5 98.45%
    Bethoxazin(Bethoguard) is a new broad spectrum industrial microbicide with applications in material and coating preservation.
    Bethoxazin
  • HY-17535
    Methasulfocarb 66952-49-6
    Methasulfocarb is a fungicide compound.
    Methasulfocarb
  • HY-18666
    D77 497836-10-9
    D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).
    D77
  • HY-P0274
    PGLa 102068-15-5
    PGLa, a 21-residue peptide, is an antimicrobial peptide. PGLa is a member of the magainin family of antibiotic peptides found in frog skin and its secretions.
    PGLa
  • HY-I0512
    Sofosbuvir impurity I 2164516-85-0
    Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity I
  • HY-I0726
    Enantiomer of Sofosbuvir 99.68%
    Enantiomer of Sofosbuvir is an enantiomer of Sofosbuvir, a prescription medicine for the treatment of patients with chronic hepatitis C. There is no biological activity report on enantiomer of Sofosbuvir until now.
    Enantiomer of Sofosbuvir
  • HY-I0735
    Sofosbuvir impurity M 2095551-10-1 99.04%
    Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity M
  • HY-I0938
    Sofosbuvir impurity H 99.72%
    Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity H
  • HY-I0975
    Sofosbuvir impurity J 1334513-10-8
    Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity J
  • HY-I1196
    Sofosbuvir impurity L 99.31%
    Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity L
  • HY-P0289
    CEF3 199727-62-3
    CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.
    CEF3
  • HY-P0304
    CEF4 199727-68-9
    CEF4 is a peptide that corresponds to aa 342-351 of the influenza A virus nucleocapsid protein.
    CEF4
  • HY-P0313
    CEF6 913545-15-0
    CEF6 is a 9-aa-long peptide corresponding to aa 418-426 of the influenza A virus (H1N1) nucleocapsid protein.
    CEF6
  • HY-P0323
    GP(33-41) 161928-86-5
    GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM.
    GP(33-41)
  • HY-101506
    2,4,6-Tribromophenyl caproate 16732-09-5 98.29%
    2,4,6-Tribromophenyl caproate (2,4,6-tribromophenyl caproic acid ester) is an anti-fungal agent.
    2,4,6-Tribromophenyl caproate
  • HY-15005C
    Sofosbuvir impurity A 1496552-16-9
    Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity A
  • HY-U00194
    Vebufloxacin 79644-90-9
    Vebufloxacin (Flumenique; OPC7241; DM8966) exhibits potent antibacterial activity against gram-positive and -negative bacteria.
    Vebufloxacin
  • HY-U00389
    WQ3810 888032-58-4
    WQ3810 is an orally active fluoroquinolone, with potent antibacterial activities.
    WQ3810
  • HY-101819
    Antibacterial compound 1 232951-56-3
    Antibacterial compound 1 is a oxazolidinone extracted from patent WO1999037630A1 with antibacterial activities.
    Antibacterial compound 1
Cat. No. Product Name / Synonyms Application Reactivity